Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
J-BALLAD adjuvant CAPOX versus observation for resected small bowel adenocarcinoma
jRCTs031180008Active, not recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Sep 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of capecitabine and oxaliplatin in small bowel adenocarcinoma (SBA) (2 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Relapse-free survival. Started Sep 2017; status: active, not recruiting.
02
Drugs
capecitabineoxaliplatin
03
Conditions
small bowel adenocarcinoma (SBA)
Beyond the preview
Go deeper on jRCTs031180008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180008.